Ignite Creation Date:
2024-05-06 @ 4:09 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04895358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-04
First Post:
2021-05-17
Brief Title:
Study of Pembrolizumab MK-3475 Plus Chemotherapy Versus Placebo Plus Chemotherapy for HRHER2- Locally Recurrent Inoperable or Metastatic Breast Cancer MK-3475-B49KEYNOTE-B49
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Neoplasms |
Keywords:
| Name | View |
|---|---|
| programmed cell death receptor 1 PD-1 PD1 | View |
| programmed cell death receptor ligand 1 PD-L1 PDL1 | View |
| programmed cell death receptor ligand 2 PD-L2 PDL2 | View |
| human epidermal growth factor 2 negative HER2- | View |
| hormone receptor positive HR | View |
| estrogen receptor positive ER | View |
| progesterone receptor positive PR | View |
| metastatic | View |
| inoperable | View |